You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 146 No. 9, September 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Primary Chemotherapy for Localized Non-Hodgkin's Lymphomas With Diffuse Histologic Characteristics

Preliminary Report of a Prospective Study

German A. Gomez, MD; Satyanarayan Reddy, MD; Ramachandra M. Krishnamsetty, MD; Maurice Barcos, MD, PhD; Hector Nava, MD; Tin Han, MD; Howard Ozer, MD, PhD; Edward S. Henderson, MD

Arch Intern Med. 1986;146(9):1785-1788.


Abstract

• Thirty-three patients with diffuse non-Hodgkin's lymphoma (stages I and II) received intermediate doses of oral methotrexate followed by leucovorin calcium every four weeks, on days 1 and 8, followed on day 15 by intravenous cyclophosphamide and vincristine sulfate. Prednisone was given for four weeks on alternate courses of treatment. A total of six such four-week courses was planned. Involved-field radiation (3000 or 3600 rad [30 or 36 Gy]) was given between three courses of chemotherapy to 18 patients who presented with tumors exceeding 7 cm in greatest diameter and who had responded to the initial chemotherapy. On completion of treatment, 27 patients (82%) were in complete remission; all the failures were in patients with large intra-abdominal masses. The presence of high lactate dehydrogenase levels, large tumor size, and age over 60 years had a suggestive negative correlation with the achievement of complete remission. The median follow-up was 26 months (range, ten to 59 months). At 48 months, the actuarial disease-free survival, remission duration, and overall survival were 53%, 72%, and 68% respectively. No deaths from toxic effects and no septic episodes were observed during treatment. The complete remission rate achieved with this program is comparable with those of other intensive programs of treatment reported previously.

(Arch Intern Med 1986;146:1785-1788)



Author Affiliations

From the Departments of Medical Oncology (Drs Gomez, Reddy, Han, Ozer, and Henderson), Radiation Therapy (Dr Krishnamsetty), Pathology (Dr Barcos), and Surgical Oncology (Dr Nava), Roswell Park Memorial Institute, Buffalo. Dr Reddy is a clinical fellow in the Department of Medical Oncology, Roswell Park Memorial Institute, Buffalo.


Footnotes

Accepted for publication Jan 2, 1986.

Reprint requests to Department of Medical Oncology, Roswell Park Memorial Institute, 666 Elm St, Buffalo, NY 14263 (Dr Gomez).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.